GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Qiagen NV (NYSE:QGEN) » Definitions » Cyclically Adjusted PS Ratio

Qiagen NV (Qiagen NV) Cyclically Adjusted PS Ratio : 5.21 (As of May. 20, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Qiagen NV Cyclically Adjusted PS Ratio?

As of today (2024-05-20), Qiagen NV's current share price is $45.47. Qiagen NV's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $8.73. Qiagen NV's Cyclically Adjusted PS Ratio for today is 5.21.

The historical rank and industry rank for Qiagen NV's Cyclically Adjusted PS Ratio or its related term are showing as below:

QGEN' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 4.11   Med: 5.69   Max: 8.75
Current: 5.23

During the past years, Qiagen NV's highest Cyclically Adjusted PS Ratio was 8.75. The lowest was 4.11. And the median was 5.69.

QGEN's Cyclically Adjusted PS Ratio is ranked worse than
75.94% of 133 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.35 vs QGEN: 5.23

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Qiagen NV's adjusted revenue per share data for the three months ended in Mar. 2024 was $2.025. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $8.73 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Qiagen NV Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Qiagen NV's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qiagen NV Cyclically Adjusted PS Ratio Chart

Qiagen NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.55 8.26 7.78 6.17 5.23

Qiagen NV Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.67 5.48 4.86 5.23 4.93

Competitive Comparison of Qiagen NV's Cyclically Adjusted PS Ratio

For the Diagnostics & Research subindustry, Qiagen NV's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Qiagen NV's Cyclically Adjusted PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Qiagen NV's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Qiagen NV's Cyclically Adjusted PS Ratio falls into.



Qiagen NV Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Qiagen NV's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=45.47/8.73
=5.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Qiagen NV's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Qiagen NV's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=2.025/128.5800*128.5800
=2.025

Current CPI (Mar. 2024) = 128.5800.

Qiagen NV Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 1.472 99.240 1.907
201409 1.492 99.960 1.919
201412 1.567 99.050 2.034
201503 1.346 99.750 1.735
201506 1.443 100.230 1.851
201509 1.420 100.500 1.817
201512 1.334 99.730 1.720
201603 1.290 100.310 1.654
201606 1.445 100.260 1.853
201609 1.459 100.570 1.865
201612 1.577 100.710 2.013
201703 1.351 101.440 1.712
201706 1.546 101.370 1.961
201709 1.612 102.030 2.031
201712 1.765 101.970 2.226
201803 1.523 102.470 1.911
201806 1.663 103.100 2.074
201809 1.657 103.950 2.050
201812 1.789 103.970 2.212
201903 1.539 105.370 1.878
201906 1.691 105.840 2.054
201909 1.742 106.700 2.099
201912 1.871 106.800 2.253
202003 1.652 106.850 1.988
202006 1.953 107.510 2.336
202009 2.115 107.880 2.521
202012 2.508 107.850 2.990
202103 2.517 108.870 2.973
202106 2.521 109.670 2.956
202109 2.375 110.790 2.756
202112 2.591 114.010 2.922
202203 2.815 119.460 3.030
202206 2.311 119.050 2.496
202209 2.239 126.890 2.269
202212 2.229 124.940 2.294
202303 2.105 124.720 2.170
202306 2.213 125.830 2.261
202309 2.127 127.160 2.151
202312 2.275 126.450 2.313
202403 2.025 128.580 2.025

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Qiagen NV  (NYSE:QGEN) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Qiagen NV Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Qiagen NV's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Qiagen NV (Qiagen NV) Business Description

Address
Hulsterweg 82, Venlo, LI, NLD, 5912 PL
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (over 45% of 2022 sales), followed by EMEA (nearly 35%), and Asia-Pacific (nearly 20%).
Executives
Prof. Dr. Elaine R. Mardis Supervisory Board
Roland Sackers Board of Directors
Thierry Bernard Board of Directors
Lawrence A. Rosen Supervisory Board